Fatality owing to pulmonary hemorrhage following pamidronate disodium administration in a neonate with osteogenesis imperfecta type 2: a case report release_dwzvoes445ew5elh5aglmedzmi

by Rintaro Nagoshi, Shoichiro Amari, Yu Abiko, Yuka Sano Wada, Akira Ishiguro, Reiko Horikawa, Yushi Ito

Published in Clinical Pediatric Endocrinology by Japanese Society for Pediatric Endocrinology.

2024   Volume 33, Issue 2, p76-81

Abstract

We report the case of a patient with osteogenesis imperfecta (OI) who developed pulmonary hemorrhage 4 d after pamidronate disodium (PA) administration, despite a relatively stable respiratory status. Bisphosphonates are introduced to reduce osteoclast activity and are now widely used in patients with OI. Bisphosphonates are typically well-tolerated in children, and the standard of care involves cyclic intravenous administration of PA. However, in practice, there is limited experience with the use of PA for severe OI during the neonatal period, and its safety remains uncertain. This report aimed to describe the respiratory events potentially associated with PA in a neonatal patient with OI type 2, suggesting that serious life-threatening complications of pulmonary hemorrhage may occur after PA administration. Further studies are required to assess the relationship between pulmonary hemorrhage and PA administration, aiming to enhance prophylaxis measures.
In text/plain format

Archived Files and Locations

application/pdf   426.2 kB
file_b2td3bfgpvcxfcuhdnnzvkqet4
www.jstage.jst.go.jp (repository)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2024-02-09
Language   en ?
Container Metadata
Open Access Publication
Not in DOAJ
In ISSN ROAD
In Keepers Registry
ISSN-L:  0918-5739
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 01df060c-61ba-48e6-ade2-4537beea0365
API URL: JSON